Business Context and Reporting Period
This Form 8-K was filed by Histogenics Corporation (not Ocugen, Inc.) on June 17, 2015. The report details the appointment of a new Chief Financial Officer and the resignation of the interim CFO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.
- Base Salary (New CFO): $315,000 annually.
- Target Bonus: 40% of annual base salary.
- Initial Stock Option: 110,000 shares vesting over four years (25% after year one).
- Performance Stock Option: 30,000 shares contingent on stock price reaching $19.92 for 60 consecutive days within four years.
Material Changes
The primary material change is the leadership transition in the finance department:
- Resignation: Stephen J. DiPalma will resign as Interim Chief Financial Officer effective July 2, 2015.
- Appointment: Jonathan Lieber was hired as Chief Financial Officer, effective July 2, 2015.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the new CFO's background and the terms of his employment agreement. Mr. Lieber brings prior experience as CFO for Metamark Genetics, Repligen Corporation, and Xcellerex, Inc. The filing notes that the Performance Grant is subject to specific stock price milestones and holding period requirements to align executive interests with shareholder value.
Investor Verification Checklist
- Verify the effective date of the CFO transition (July 2, 2015).
- Confirm the vesting schedule and exercise price for the 110,000 initial stock options.
- Monitor the stock price to assess the feasibility of the $19.92 performance target for the 30,000 performance shares.
- Review the full Employment Agreement (Exhibit 10.38) for additional terms not summarized in the 8-K.